SCHEMBL30689129

SCHEMBL30689129

CC[C@H](C)[C@H](NS(=O)(=O)c1ccc(C)cc1)C(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
MMP13 P45452 2/20 0.52
ADAMTS4 O75173 1/20 0.52
CA2 P00918 6/20 0.50
CA1 P00915 5/20 0.50
LMNA P02545 2/20 0.50
MMP9 P14780 2/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP3 P08254 1/20 0.50
MMP7 P09237 1/20 0.50
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RAB9A P51151 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
GAA P10253 1/20 0.48
SLC1A3 P43003 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30689139 0.90 ALDH1A1 (0.54) ALDH1A1MMP13ADAMTS4CA2CA1
SCHEMBL30689121 0.90 ADAMTS4 (0.60) ALDH1A1MMP13ADAMTS4CA2CA1
SCHEMBL30689105 0.85 ALDH1A1 (0.56) ALDH1A1MMP13ADAMTS4CA2CA1
SCHEMBL28736941 0.84 CA2 (0.48) ALDH1A1MMP13ADAMTS4CA2CA1
SCHEMBL29619298 0.84 LMNA (0.48) CA2CA1LMNACYP3A4CYP2D6
SCHEMBL5221010 0.84 LMNA (0.55) ALDH1A1MMP13ADAMTS4CA2CA1
SCHEMBL29883707 0.81 CTSL (0.54) ALDH1A1MMP13CA2CA1LMNA
SCHEMBL13335276 0.81 SMN1; SMN2 (0.50) MMP13ADAMTS4MMP9MMP1MMP2
SCHEMBL21538660 0.81 MMP9 (0.69) MMP13ADAMTS4CA2CA1LMNA
SCHEMBL28216417 0.81 MMP9 (0.69) MMP13ADAMTS4CA2CA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312644-A1 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) 2023-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312644-A1 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING SERPINC1, PLAT, F2 ALDH1A1 1478/4885MMP13 55/4885ADAMTS4 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.